Sign In

Saturday, March 18, 2017 - 8:00 am to Sunday, March 19, 2017 - 12:00 pm

Emerging Trends in Non-Alcoholic Fatty Liver Disease

Note: This event was held March 18-19, 2017 in Washington, DC.

Attendees at this conference met to develop a strategy to disseminate new knowledge and treatment options in NAFLD.

Program Chairs

  • Zobair M. Younossi, MD, MPH, FAASLD
  • Keith D. Lindor, MD, FAASLD

Course Syllabus

Download the course syllabus [PDF].

Captured Content Available Now in LiverLearning®

Captured sessions from this conference are available in LiverLearning®. You will need to log in with your AASLD username and password to access the content.

 

Session I: Definition, Diagnosis and Outcomes

Saturday, March 18, 2017
Moderators: Elisabetta Bugianesi, MD, PhD and Stephen H. Caldwell, MD, FAASLD

  • 8-8:05 am
    Welcome and Opening Remarks
    Zobair M. Younossi, MD, MPH, FAASLD and Keith D. Lindor, MD, FAASLD
  • 8:05-8:25 am
    Clinical, Epidemiologic, Patient-Reported and Economic Burden of NAFLD
    Zobair M. Younossi, MD, MPH, FAASLD
  • 8:25-8:45 am
    Long Term Outcomes: Mortality and Causes of Death in NAFLD
    Mary E. Rinella, MD, FAASLD
  • 8:45-9:05 am
    Will The Epidemic of NAFLD Be Responsible for the Future Burden of HCC?
    Elisabetta Bugianesi, MD, PhD
  • 9:05-9:15 am
    Q&A

Session II: Metabolic Syndrome and NASH

Saturday, March 18, 2017
Moderators: Lawrence Serfaty, MD and Stephen A. Harrison, MD, FAASLD

  • 9:15-9:35 am
    Is MS the Consequence or Precursor of NASH?
    Giulio Marchesini, MD
  • 9:35-9:55 am
    Insulin Resistance in NAFLD
    Brent A. Tetri, MD, FAASLD
  • 9:55-10:15 am
    Lipid Abnormalities in NAFLD
    Lawrence Serfaty, MD
  • 10:15-10:35 am
    Cardiovascular Diseases and NAFLD
    Francesco Negro, MD
  • 10:35-10:45 am
    Q&A
  • 10:45-10:55 am
    Break

Session III: Pathogenic Mechanisms

Saturday, March 18, 2017
Moderators: Brent A. Tetri, MD, FAASLD and Zachary D. Goodman, MD, PhD, FAASLD

  • 10:55-11:15 am
    The Role of Mitochondria and Endoplasmic Reticulum in NASH Pathogenesis
    Stephen H. Caldwell, MD, FAASLD
  • 11:15-11:35 am
    The Role White Adipose Tissue in NASH
    Vlad Ratziu, MD
  • 11:35-11:55 am
    NAFLD and Microbiome
    Kathleen E. Corey, MD, MPH
  • 11:55 am-12:15 pm
    Fibrogenesis of NASH: What Is Different About It?
    Scott L. Friedman, MD, FAASLD
  • 12:15-2:35 pm
    Experimental Models of NAFLD: Do They Represent the Human Disease?
    Manal F. Abdelmalek, MD, MPH, FAASLD
  • 12:35-12:45 pm
    Q & A
  • 12:45-1:30 pm
    Lunch

Session IV: Special Topics in NASH

Saturday, March 18, 2017
Moderators: Philippe Mathurin, MD, PhD and Michael R. Charlton, MD

  • 1:30-1:50 pm
    Racial and Ethnic Differences in Nonalcoholic Fatty Liver Disease
    Arun J. Sanyal, MD, FAASLD
  • 1:50-2:10 pm
    Nonalcoholic Fatty Liver Disease in Children: Not a Tiny Matter
    Joel E. Lavine, PhD, FAASLD
  • 2:10-2:30 pm
    NASH and Bariatric Surgery
    Philippe Mathurin, MD, PhD
  • 2:30-2:50 pm
    NASH and Liver Transplantation
    Michael R. Charlton, MD
  • 2:50 pm-3 pm
    Q & A
  • 3:00-3:10 pm
    Break

Session V: Oral Presentations

Saturday, March 18, 2017
Moderators: Francesco Negro, MD and Rohit Loomba, MD

  • 3:10-3:25 pm
    Steatosis, Portal Inflammation and Fibrosis are More Advanced in Younger Children with Non-Alcoholic Fatty Liver Disease (NAFLD) 
    Reham Abdou, MD
  • 3:25-3:40 pm
    The Association of Histologic Activity with Long Term Outcomes of Patients with Non-alcoholic Fatty Liver Disease
    Maria Stepanova, PhD
  • 3:40-3:55 pm
    Predicting the Degree of Liver-Biopsy-Confirmes Steatosis and Fibrosis Using Transient Elastography and Magnetic Resonance Imaging-Based Techniques in Adult Patients with Suspected Non-Alcoholic Fatty Liver Disease 
    Stephen A. Harrison, MD, FAASLD
  • 3:55- :10 pm
    Impact of a Structured Exercise, Nutrition and Patient Education Program on Short Term Outcomes in Patients with Non-Alcoholic Fatty Liver Disease
    Monica A. Konerman, MD
  • 4:10-4:25 pm
    VLX103, a New Hepatoselective Investigational Drug Targeting the LPS-TLR4 Pathway in Non-Alcoholic Liver Disease
    Patrick Colin, BPharm, PhD
    * No CME credits/MOC points are available for this oral presentation
  • 4:25-4:40 pm
    The Comparative Effect of Liraglutide, Elafibranor and Obeticholic Acid on NAFLD Activity Score and Fibrosis Stage in a Diet-Induced Obese Mouse Model of Biopsy-Confirmed Non-Alcoholic Steatohepatitis
    Michael Feigh, MD
    * No CME credits/MOC points are available for this oral presentation
  • 4:40-5:30 pm
    Reception and Poster Viewing
    *No CME credits/MOC points are available for this session

Session VI: Endpoints

Sunday, March 19, 2017
Moderators: Kris V. Kowdley, MD, FAASLD and Naga P. Chalasani, MD

  • 8-8:20 am
    Role of Histopathology in the Clinical Research and Clinical Management of Patients with NAFLD
    Zachary D. Goodman, MD, PhD, FAASLD
  • 8:20-8:40 am
    The Role Radiologic Modalities for Diagnosing, Staging and Monitoring NASH
    Rohit Loomba, MD
  • 8:40 am - 9:00 am
    Noninvasive Biomarkers in NASH
    Naga P. Chalasani, MD
  • 9-9:20 am
    Serum Fibrosis Markers in NASH
    Quentin M. Anstee, MBBS, PhD
  • 9:20-9:40 am
    What Are the Best Endpoints for the Clinical Trials of NASH: Investigator and Regulatory Perspective
    Kris V. Kowdley, MD, FAASLD
  • 9:40-9:50 am
    Q & A
  • 9:50 am-10 am
    Break

Session VII: Emerging Therapies

Sunday, March 19, 2017
Moderators: Zobair M. Younossi, MD, MPH, FAASLD and Keith D. Lindor, MD, FAASLD

  • 10-10:20 am
    Weight Loss and Exercise in NAFLD
    Jacob George, PhD, FAASLD
  • 10:20-10:40 am
    The Current Medical Treatment for Patients with NASH
    Manal F. Abdelmalek, MD, MPH, FAASLD
  • 10:40-11 am
    Emerging Therapy for NASH: Non-Antifibrotics
    Stephen A. Harrison, MD, FAASLD
  • 11-11:20 am
    Emerging Therapy for NASH: Antifibrotics
    Scott L. Friedman, MD, FAASLD
  • 11:20-11:30 am
    Q & A
  • 11:30-11:50 am
    Summary of the Meeting: What to Do Next?
    Keith D. Lindor, MD, FAASLD
  • 11:50 am-Noon
    Closing Remarks
    Zobair M. Younossi, MD, MPH, FAASLD
  • Noon
    Adjourn